The open-label, multi-center Phase Ⅱ clinical study is led by Professor Shen Lin of Beijing Cancer Hospital and is being conducted across multiple hospitals in China. The trial aims to evaluate the ...
Everyday Health on MSN
What is PD-L1, and why does it matter?
A PD-L1 score for head and neck cancer helps guide treatment decisions, including when immunotherapy may be used. Here’s what your results mean.
Translational study in metastatic triple-negative breast cancer (mTNBC) shows leronlimab-mediated CCR5 inhibition induces PD-L1 expression, ...
The U.S. FDA has granted Fast Track designation for mRNA-4359 in combination with pembrolizumab for the treatment of ...
In this video, Ursula A. Matulonis, MD, shares insight on the phase 3 KEYNOTE-B96 trial of pembrolizumab combination therapy vs. placebo in patients with PD-L1-positive, platinum-resistant ovarian ...
A total of 20 patients were included in the safety run-in cohort and completed preliminary evaluation. Results demonstrated that Opamtistomig in combination with chemotherapy was generally well ...
The results suggest the drug boasts similar safety and efficacy in non-small cell lung cancer compared with the field’s ...
A new research paper was published in Volume 17 of Oncotarget on March 31, 2026, titled “Efficacy and safety of PD-1/ PD-L1 ...
The FDA is having second thoughts about the broad labels it has granted PD-1 inhibitors in newly diagnosed stomach cancer, questioning whether restrictions should be placed on products from Bristol ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results